Solutions

Repurposing drugs for new indications and routes of administration

How AI generates unprecedented drug repurposing insights, accelerating development and reducing program risk.

Introduction

Bringing a novel drug to market is a slow, costly and laborious endeavor – with a notoriously high risk of failure.

Drug repurposing, in which new uses are discovered for already pre-approved or existing drugs, offers a faster, more streamlined approach to take a new candidate therapy from the scientist’s bench to a patient’s bedside.

Today, advances in technology have enabled systematic approaches to identifying and translating repurposable compounds – giving a second chance to de-risked, ‘old’ medicines, and significantly reducing development costs and timelines along the way.

Download PDF
Situation

Though systematic drug repurposing has clear advantages in the context of drug development, some challenges remain.  When it comes to drug repurposing, there are two primary categories of approaches: experimental and computational

Quote

The VeriSIM Life advantage

Computational and artificial intelligence (AI) technologies have advanced rapidly to meet the challenges of drug repurposing and reformulation head on.

VeriSIM Life’s drug decision engine, BIOiSIM®, is a computational platform deploying advanced artificial intelligence and machine learning, a proprietary big data foundation, and state-of- the-art mechanistic models to develop novel therapies from existing molecules.

BIOiSIM®, and its groundbreaking Translational Index™️ technology

Which advances only the most promising drug candidates through R&D to investigational new drug (IND) application, offers actionable insights of unprecedented value to the drug development industry.

Combining thousands of validation data sets, multi-compartmental models, and its integrated AI/ML engine, BIOiSIM® achieves superior physiological and biological relevance within three classes of therapeutics: small molecules, large molecules, and re-engineered viruses.

The BIOiSIM® platform features a
robust data lake foundation, integrating:

1 trillion potential compounds search space for de novo synthesis and structural screening

1 trillion potential compounds search space for de novo synthesis and structural screening

Physiological data from 7 different animal species, plus humans

Physiological data from 7 different animal species, plus humans

Support for genomics data integration

Support for genomics data integration

More than 3,000,000 real compounds including proprietary data from multiple partnerships

More than 3,000,000 real compounds including proprietary data from multiple partnerships

Proprietary experimental data from scientific literature and other sources

Proprietary experimental data from scientific literature and other sources

Validation by real-world observed data

Validation by real-world observed data

For the repurposing of therapeutics with an established mechanism-of-action, BIOiSIM® can also be used to simulate and predict the pharmacokinetics (PK) and pharmacodynamics (PD) of compounds that are known to match the targeted pathway. Similar predictive simulation capabilities can guide the development of new drug combinations – using the application of machine learning to predict drug pathways and anticipated disease response in lieu of experimental data.

Proof of Value

Optimizing dosing and route of administration with BIOiSIM®

Challenge

Challenge

VeriSIM Life’s biotech client needed to determine the feasibility of repurposing and developing a topical formulation for erectile dysfunction, which contained  a combination of three known drugs.

Solution

Solution

VeriSIM Life’s biotech client leveraged BIOiSIM’s® transdermal model to repurpose compounds for topical application. After a seamless, three-step process, the platform recommended a therapeutic drug window for the three compounds.

Methods

Methods

  • Data import and automated screening.
  • ML model clustering, fine-tuning, and simulation.
  • Model evaluation and analysis with test compounds.
Outcome

Outcome

BIOiSIM® identified a different route of administration, validated therapeutic window and predicted optimal dosing for three compound- mixes, with 80%+ accuracy. Predictions were ultimately validated by a CRO and the client has now filed IP and applied for IND approval.

Quote
Quote

Without VSL’s insights, we couldn’t have gained the confidence to approach a CRO and invest money in further experiments.

- CEO, Biotech Client
Case studies

Additional VeriSIM Life Case Studies & Content

01

Accelerating SUD Therapy Discovery with AI/ML Driven BBB Permeability Predictions

Read the full article
02

Pathways for Successful AI Adoption in Drug Development

Read the full article
Evolve your pipeline

Bring better drugs to market, faster, with BIOiSIM®

Now you can accelerate the discovery of new therapies based on existing compounds with VeriSIM Life’s BIOiSIM® computational platform – purpose-built to decode chemistry and biology at scale. With the industry’s most generalistic AI platform, your innovation is no longer limited to experimental constraints.

Contact us today to schedule a demonstration of BIOiSIM®